In a recent study, zoledronic acid decreased the incidence of skeletal-related events (SREs) and improved one-year survival in patients with bone metastases from bladder cancer, according to a study.

Mohamed S. Zaghloul, MD, of Cairo University in Egypt, and colleagues randomized 40 such patients to receive zoledronic acid (4 mg IV monthly) or placebo for six months.

Zoledronic acid decreased SRE risk by 59% and prolonged the median time to first SRE compared with placebo (16 vs. 8 weeks).

Continue Reading

The one-year survival rate was 36.3% in the zoledronic acid group compared with 0% in the placebo arm, researchers reported in the International Journal of Clinical Oncology (published online ahead of print).